GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Swedish Orphan Biovitrum AB (OTCPK:BIOVF) » Definitions » 3-Year EPS without NRI Growth Rate

BIOVF (Swedish Orphan Biovitrum AB) 3-Year EPS without NRI Growth Rate : 10.70% (As of Dec. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Swedish Orphan Biovitrum AB 3-Year EPS without NRI Growth Rate?

Swedish Orphan Biovitrum AB's EPS without NRI for the three months ended in Dec. 2024 was $0.36.

During the past 12 months, Swedish Orphan Biovitrum AB's average EPS without NRI Growth Rate was 38.00% per year. During the past 3 years, the average EPS without NRI Growth Rate was 10.70% per year. During the past 5 years, the average EPS without NRI Growth Rate was 0.30% per year. During the past 10 years, the average EPS without NRI Growth Rate was 49.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Swedish Orphan Biovitrum AB was 253.40% per year. The lowest was -46.10% per year. And the median was -2.50% per year.


Competitive Comparison of Swedish Orphan Biovitrum AB's 3-Year EPS without NRI Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Swedish Orphan Biovitrum AB's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Swedish Orphan Biovitrum AB's 3-Year EPS without NRI Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Swedish Orphan Biovitrum AB's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Swedish Orphan Biovitrum AB's 3-Year EPS without NRI Growth Rate falls into.


;
;

Swedish Orphan Biovitrum AB 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Swedish Orphan Biovitrum AB  (OTCPK:BIOVF) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


Swedish Orphan Biovitrum AB 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Swedish Orphan Biovitrum AB's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Swedish Orphan Biovitrum AB Business Description

Address
Tomtebodavagen 23 A, Solna, Stockholm, SWE, SE-112 76
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) in 2006 on long-acting hemophilia factor replacement programs. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016, and Altuvoct in 2024. Sobi has been building its immunology pipeline (rare-disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drug SEL-212, complement drug Aspaveli) and a broader hematology pipeline (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).